William Trenton Webb Sells 1,794 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Key Points

• Insider sale: Director William Trenton Webb sold 1,794 shares on March 5 at an average price of $13.86 (and an additional 272 shares on March 6), reducing his stake by 2.42% to 72,455 shares valued at about $1.00M.
• Earnings miss but revenue beat: Q4 EPS came in at $0.12 versus consensus $0.31 while revenue was $885M (above expectations) and up 2.4% year-over-year, with the stock trading near $13.30 (50-day/200-day SMAs $15.16/$18.00).
• Corporate actions and mixed sentiment: The board approved a $200M buyback (up to ~9.7% of shares) amid a "Moderate Buy" analyst consensus and a consensus $24.45 target, but the company faces a shareholder fraud probe and notable insider selling that may weigh on sentiment.

Surgery Partners, Inc. (NASDAQ:SGRY - Get Free Report) insider William Trenton Webb sold 1,794 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $13.86, for a total transaction of $24,864.84. Following the completion of the sale, the insider owned 72,455 shares in the company, valued at $1,004,226.30. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

William Trenton Webb also recently made the following trade(s):

• On Friday, March 6th, William Trenton Webb sold 272 shares of Surgery Partners stock. The shares were sold at an average price of $13.93, for a total value of $3,788.96.

Surgery Partners Trading Down 0.4%

Shares of SGRY traded down $0.06 during trading hours on Monday, hitting $13.30. The stock had a trading volume of 1,453,571 shares, compared to its average volume of 1,733,344. The company's fifty day simple moving average is $15.16 and its 200 day simple moving average is $18.00. The firm has a market cap of $1.72 billion, a P/E ratio of -21.45 and a beta of 1.95. Surgery Partners, Inc. has a 12-month low of $12.25 and a 12-month high of $24.60. The company has a debt-to-equity ratio of 1.15, a quick ratio of 1.71 and a current ratio of 1.87.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.31 by ($0.19). Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.The company had revenue of $885.00 million during the quarter, compared to analysts' expectations of $866.54 million. During the same quarter in the prior year, the company earned $0.44 EPS. The firm's revenue was up 2.4% compared to the same quarter last year. Equities research analysts forecast that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.

Surgery Partners announced that its Board of Directors has initiated a stock repurchase program on Thursday, February 26th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to reacquire up to 9.7% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SGRY. Weiss Ratings reissued a "sell (e+)" rating on shares of Surgery Partners in a report on Monday, December 29th. Mizuho decreased their price target on shares of Surgery Partners from $19.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday. JPMorgan Chase & Co. cut their price target on shares of Surgery Partners from $27.00 to $20.00 and set a "neutral" rating on the stock in a report on Monday, November 24th. Jefferies Financial Group reiterated a "buy" rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Finally, Barclays decreased their target price on shares of Surgery Partners from $18.00 to $14.00 and set an "equal weight" rating for the company in a research report on Tuesday, March 3rd. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $24.45.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of SGRY. State of Wisconsin Investment Board raised its stake in shares of Surgery Partners by 0.4% in the fourth quarter. State of Wisconsin Investment Board now owns 151,504 shares of the company's stock worth $2,341,000 after acquiring an additional 668 shares during the last quarter. ProShare Advisors LLC grew its holdings in Surgery Partners by 6.9% during the 4th quarter. ProShare Advisors LLC now owns 14,135 shares of the company's stock worth $218,000 after acquiring an additional 909 shares during the period. Jones Financial Companies Lllp grew its stake in shares of Surgery Partners by 313.1% during the third quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company's stock worth $27,000 after purchasing an additional 930 shares during the period. California State Teachers Retirement System grew its position in shares of Surgery Partners by 1.6% during the 2nd quarter. California State Teachers Retirement System now owns 65,091 shares of the company's stock worth $1,447,000 after buying an additional 1,021 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in Surgery Partners by 7.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 17,582 shares of the company's stock valued at $391,000 after purchasing an additional 1,176 shares during the period.

More Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Broker consensus: Several brokerages give SGRY an average recommendation of “Moderate Buy,” which can support demand and sentiment among growth/healthcare investors. Brokerage Recommendation
• Positive Sentiment: Investor conference: Surgery Partners will present at the Barclays 28th Annual Global Healthcare Conference (Mar 10), offering management a chance to reiterate guidance, margin plans and strategy — a potential catalyst if commentary is constructive. Conference Announcement
• Neutral Sentiment: Q4 highlights coverage: Industry write-ups summarizing outpatient and specialty care Q4 results include Surgery Partners; these summaries provide context on revenue and margin trends but add no single new catalyst. Q4 Coverage
• Neutral Sentiment: Analyst views mixed: Some outlets note mixed analyst opinions — supportive ratings exist but others highlight execution and margin risk; inconsistent analyst messaging can limit strong directional moves. Analysts Mixed
• Negative Sentiment: Shareholder fraud probe: Law firm Levi & Korsinsky has opened an investigation into potential securities law violations tied to past management statements about margin expansion — this raises legal/settlement risk and investor uncertainty. Fraud Investigation
• Negative Sentiment: Heavy insider selling: Multiple insiders — including the CEO (Jason Evans), CFO (David Doherty) and several other officers — sold shares the week of Mar 5–6 (large blocks at ~$13.60–$13.93). Concentrated insider disposals can be perceived negatively by the market; representative SEC filings available. SEC Filing (CEO Sale)

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.